# Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

> **NCT07425782** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 216 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Consolidation Therapy
- Venentoclax
- High Risk
- Hematopoietic Stem Cell Transplant (HSCT)

## Interventions

- **DRUG:** Ara-C Group
- **DRUG:** VEN/AZA condsolidation

## Key facts

- **NCT ID:** NCT07425782
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-11-26
- **Final completion:** 2028-11-26
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425782, "Venetoclax Combined With Azacitidine for Consolidation Therapy in AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07425782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*